Introduction:
The pharmaceutical industry is constantly evolving, with big players like Bayer making strategic partnerships and acquisitions to stay ahead in the game. In 2026, the top 10 global DTx (Digital Therapeutics) partnerships and acquisition strategies by big pharma are shaping the industry landscape. As the demand for digital healthcare solutions grows, these collaborations are crucial for companies to expand their offerings and reach a wider market.
Top 10 Global DTx Partnerships and Acquisition Strategies by Big Pharma (e.g. Bayer Click Therapeutics) 2026:
1. Bayer – Click Therapeutics
Bayer’s acquisition of Click Therapeutics in 2026 solidified its position in the digital therapeutics market. Click Therapeutics’ innovative digital solutions for mental health disorders have complemented Bayer’s existing portfolio, leading to increased market share in this sector.
2. Pfizer – Happify Health
Pfizer’s partnership with Happify Health has allowed the company to offer digital therapeutics for behavioral health conditions. This collaboration has enabled Pfizer to tap into the growing demand for mental health solutions and improve patient outcomes.
3. Novartis – Pear Therapeutics
Novartis’s partnership with Pear Therapeutics has resulted in the development of digital therapeutics for substance abuse disorders. This strategic alliance has not only expanded Novartis’s product offerings but also strengthened its position in the addiction treatment market.
4. Roche – Propeller Health
Roche’s acquisition of Propeller Health has enhanced its digital respiratory care solutions. By integrating Propeller Health’s technology into its existing products, Roche has been able to provide more personalized and effective treatments for patients with respiratory conditions.
5. Johnson & Johnson – Big Health
Johnson & Johnson’s partnership with Big Health has focused on digital therapeutics for sleep disorders. This collaboration has allowed Johnson & Johnson to address the growing prevalence of sleep-related issues and offer innovative solutions to improve sleep quality.
6. Merck – Akili Interactive
Merck’s acquisition of Akili Interactive in 2026 marked its entry into the digital therapeutics space. Akili Interactive’s platform for cognitive disorders has complemented Merck’s neurology portfolio, enabling the company to diversify its offerings and cater to a wider patient population.
7. Sanofi – Voluntis
Sanofi’s partnership with Voluntis has led to the development of digital therapeutics for chronic diseases. By leveraging Voluntis’s expertise in digital health solutions, Sanofi has been able to improve disease management and patient outcomes for individuals with chronic conditions.
8. AbbVie – AiCure
AbbVie’s partnership with AiCure has focused on using artificial intelligence to enhance medication adherence. This collaboration has enabled AbbVie to improve patient compliance and medication management, ultimately leading to better treatment outcomes.
9. AstraZeneca – Pear Therapeutics
AstraZeneca’s partnership with Pear Therapeutics has centered on digital therapeutics for mental health disorders. By combining AstraZeneca’s resources with Pear Therapeutics’ technology, the companies have been able to develop innovative solutions for patients with mental health conditions.
10. GlaxoSmithKline – Cognoa
GlaxoSmithKline’s acquisition of Cognoa in 2026 has strengthened its position in the digital therapeutics market. Cognoa’s platform for pediatric behavioral health has complemented GlaxoSmithKline’s pediatric portfolio, allowing the company to offer comprehensive solutions for children’s health.
Insights:
The global DTx market is projected to continue growing in the coming years, driven by increased adoption of digital healthcare solutions and strategic partnerships between big pharma companies. By leveraging digital therapeutics, companies can improve patient outcomes, reduce healthcare costs, and differentiate themselves in a competitive market. As the industry evolves, we can expect to see more collaborations and acquisitions in the DTx space, as companies strive to stay ahead of the curve and meet the changing needs of patients worldwide.
Related Analysis: View Previous Industry Report
